secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0000875320-22-000019
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Vertex enters new $500M senior unsecured revolving credit facility, replaces 2019 agreement
--------------------------------------------------------------------------------

- $500M revolving facility, matures July 1, 2027; capacity can be increased by an additional $500M.
- Interest: base rate +0.000%-0.500% or SOFR +1.000%-1.500%, based on leverage ratio or credit rating.
- Financial covenant: consolidated leverage ratio ≤3.50:1 (4.00:1 after material acquisition).
- Old 2019 credit agreement terminated and all obligations repaid; related guarantees released.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000019/0000875320-22-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000019/vrtx-20220701.htm
  HTML page:      https://secwatch.observer/filing/0000875320-22-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer